Research Topics
| B FaliniSummaryAffiliation: University of Perugia Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistryBrunangelo Falini
Institute of Hematology, University of Perugia, Italy
Blood 99:409-26. 2002....- Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AMLBrunangelo Falini
Institute of Hematology, University of Perugia, 06122 Perugia, Italy
Blood 107:4514-23. 2006..These findings indicate that potential therapeutic strategies aimed to retarget NPM to its physiological sites will have to overcome 2 obstacles, the new NES motif and the mutated tryptophan(s) at the NPM mutant C-terminus... - Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemiasBrunangelo Falini
Section of Haematology and Immunology, University of Perugia, IBiT Foundation, Perugia, Italy
Haematologica 92:519-32. 2007..The discovery of NPM1 gene alterations also represents the rationale basis for development of molecular targeted drugs... 
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemiaEnrico Tiacci
Institute of Hematology, Ospedale S Maria della Misericordia, University of Perugia, Perugia, Italy
Haematologica 98:635-9. 2013....- IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomasBrunangelo Falini
Institute of Haematology, University of Perugia, Ospedale S Maria della Misericordia, Perugia, Italy
Histopathology 61:930-41. 2012..The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas... 
Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, UgandaLynnette K Tumwine
Department of Pathology, Makerere University, College of Health Sciences, PO Box 7072, Kampala, Uganda
BMC Clin Pathol 9:11. 2009..Such studies are lacking in Africa where diagnosis is largely dependent on morphology alone. We report immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients in Kampala, Uganda...- Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT)Brunangelo Falini
Institute of Hematology, University of Perugia, 06122 Perugia, Italy
Blood 102:3684-92. 2003..Collectively, these results suggest a role of IRTA1 in the immune function of B cells within epithelia... - Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1)Brunangelo Falini
Institute of Haematology, University of Perugia, Perugia, Italy
Lancet 363:1869-70. 2004.... - Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical featuresBrunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy
Cancer Treat Res 145:149-68. 2010.... - Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)Brunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy
Blood 115:3776-86. 2010..Our findings indicate that NPM1 mutations rather than MLD dictate the distinctive features of NPM1-mutated AML. Thus, irrespective of MLD, NPM1-mutated AML represents one disease entity clearly distinct from AML with MRCs... - Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implicationsB Falini
The Institute of Haematology, University of Perugia, IBiT Foundation, Fondazione IRCCS Biotecnologie nel Trapianto, Perugia, Italy
Leukemia 23:1731-43. 2009..Finally, we discuss the future therapeutic perspectives aimed at reversing the altered nucleophosmin transport in AML with mutated NPM1... - Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities?Brunangelo Falini
Institute of Hematology, Perugia University, Perugia, Italy
Leuk Lymphoma 48:2093-5. 2007 - Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID miceBrunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy
Haematologica 93:775-9. 2008.... - Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?Brunangelo Falini
Institute of Hematology, University of Perugia, Ospedale S Maria della Misericordia, S Andrea delle Fratte, Perugia, Italy
Blood 117:1109-20. 2011..Altogether, these pieces of evidence point to NPM1-mutated AML as a founder genetic event that defines a distinct leukemia entity accounting for approximately one-third of all AML... - New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issuesBrunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy
Discov Med 10:281-92. 2010..Finally, we describe the unique characteristics of myeloid proliferations associated with Down syndrome and blastic plasmacytoid dendritic cell neoplasm... - Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemiaBrunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy
Best Pract Res Clin Haematol 23:417-31. 2010..Genome wide based discovery of new tumor-associated genetic lesions that are suitable for antibody targeting promises to further expand the application of immunohistochemistry for the molecular classification of hematological neoplasms... - Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical featuresBrunangelo Falini
Institute of Hematology, University of Perugia, Italy
Blood 109:874-85. 2007..Future studies should focus on clarifying how NPM mutants promote leukemia, integrating NPMc+ AML in the upcoming World Health Organization leukemia classification, and eventually developing specific antileukemic drugs... - A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cellsB Falini
Institutes of Hematology and Internal Medicine, University of Perugia, Perugia, Italy
Blood 95:2084-92. 2000..These results suggest that MUM1 is involved in the late stages of B-cell differentiation and in T-cell activation and is deregulated in DLCL-B. (Blood. 2000;95:2084-2092).. - Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotypeBrunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy
N Engl J Med 352:254-66. 2005..Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein... - Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?Brunangelo Falini
Institute of Hematology, Strada Sant Andrea delle Fratte, University of Perugia, 06122 Perugia, Italy
Blood Rev 25:247-54. 2011.... - Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemiaBrunangelo Falini
Institute of Hematology, Policlinico Monteluce, 06122 Perugia, Italy
Blood 108:1999-2005. 2006.... - NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy
Haematologica 93:439-42. 2008..Taken together, these findings make NPMc+ acute myeloid leukemia a good candidate for inclusion in the upcoming World Health Organization classification... - A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARFN Bolli
Section of Haematology and Immunology, Department of Clinical and Experimental Medicine, University of Perugia, IBiT Foundation, Fondazione IRCCS Biotecnologie nel Trapianto, Perugia, Italy
Leukemia 23:501-9. 2009..Moreover, they provide a rationale basis for designing small molecules acting at the interface between mutated NPM1 and other interacting proteins... - Distribution of T cells bearing different forms of the T cell receptor gamma/delta in normal and pathological human tissuesB Falini
Institute of Internal Medicine, University of Perugia, Italy
J Immunol 143:2480-8. 1989..Among inflammatory conditions, an increase of BB3+ cells was observed in close association with necrotic areas in cases of Kikuchi's and tuberculous lymphadenitis. The significance of this finding is under study... - CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapyB Falini
Institute of Hematology, University of Perugia, Italy
Blood 85:1-14. 1995 - Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutationsP Gorello
Institute of Hematology, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy
Leukemia 20:1103-8. 2006..Thus, reliable, sensitive RQ-PCR assays for NPM1 mutations can now monitor and quantify MRD in AML patients with normal karyotype and NPM1 gene mutations... - ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrumB Falini
Institute of Hematology, University of Perugia, Italy
Am J Pathol 153:875-86. 1998..In conclusion, ALK positivity appears to define a clinicopathological entity with a T/null phenotype ("ALK lymphomas"), but one that shows a wider spectrum of morphological patterns than has been appreciated in the past... - Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classificationLaura Pasqualucci
Institute of Hematology, University of Perugia, Perugia, Italy
Blood 108:4146-55. 2006.... - Vaccine therapy of B cell malignancies: different strategies for a novel approachA Liso
University of Perugia, Institute of Hematology, Italy
Leuk Lymphoma 42:881-9. 2001..Previous studies will be reviewed and the present status of vaccine technology summarized... - Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VIEnrico Tiacci
Section of Physiopathology, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy
Blood 105:2812-20. 2005..Finally, the anti-TPD52 monoclonal antibody served as a valuable tool for the diagnosis of B-cell malignancies... - PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemiaEnrico Tiacci
Institutes of Hematology and Internal Medicine, University of Perugia, Perugia, Italy
Cancer Res 64:7399-404. 2004..e. the aberrant expression of B-cell genes... - Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemiaNiccolò Bolli
Institute of Haematology, Policlinico Monteluce, Perugia, Italy
Lancet Oncol 7:350-2. 2006 - CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised miceMaria Paola Martelli
Institute of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
Blood 116:3907-22. 2010..This study provides further evidence that NPM1 mutation is a founder genetic lesion and has potential implications for the cell-of-origin and targeted therapy of NPM1-mutated AML... - Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutantsNiccolò Bolli
Section of Hematology and Immunology, University of Perugia, Perugia, Italy
Cancer Res 67:6230-7. 2007..The fact that W288-retaining mutants always combine with the strongest NES reveals mutational selective pressure toward efficient export into cytoplasm, pointing to this event as critical for leukemogenesis... - Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognized by the Ki-67 monoclonal antibodyB Falini
Department of Internal Medicine, University of Perugia, Italy
J Histochem Cytochem 37:1471-8. 1989..The widespread evolutionary conservation of the human proliferation-associated epitope recognized by the Ki-67 MAb suggests that it and/or its carrier molecule may play an important role in regulation of cell proliferation... - A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)Arcangelo Liso
Institute of Hematology, University of Foggia, Foggia, Italy
Haematologica 93:1219-26. 2008..This model fits with the hypothesis that NPMc(+) acute myeloid leukemia arises from an NPM1 mutation with haploinsufficiency of the wild-type NPM1 allele... - EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissuesMaria Paola Martelli
Institute of Hematology, University of Perugia, Perugia, Italy
Am J Pathol 174:661-70. 2009..The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for NSCLC. Our results show therefore that the causal role and value of EML4-ALK as a therapeutic target remain to be defined... - Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectivesBrunangelo Falini
Institute of Hematology, University of Perugia, Perugia, Italy to Top
Curr Opin Oncol 21:573-81. 2009..The present review summarizes recent advances in the biology, diagnosis, prognosis and therapy of NPM1-mutated AML... - Immunohistochemical investigation of axillary lymph nodes for micrometastases in patients with breast cancer using E29A Cavaliere
Istituto di Anatomia e Istologia Patologica, , Perugia, Italy
Tumori 75:563-5. 1989..9%) this antibody revealed the presence of epithelial metastatic foci which had not been observed at routine histological examination or interpreted as histiocytes. The 4 lymph nodes belonged to 4 different patients... - Granular cell tumor: an immunohistochemical studyA Cavaliere
Institute of Pathological Anatomy and Histology, Perugia University, Italy
Tumori 80:224-8. 1994.... - Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptorsKatia Basso
Institute of Hematology, Policlinico Monteluce, Perugia 06100, Italy
J Exp Med 199:59-68. 2004..These results have biological implications relevant to the pathogenesis of this malignancy as well as clinical implications for its diagnosis and therapy... - Homing and survival of thymidine kinase-transduced human T cells in NOD/SCID miceMauro Di Ianni
Hematology and Clinical Immunology Section, Department of Clinical and Experimental Medicine, Perugia University, Perugia, Italy
Cancer Gene Ther 9:756-61. 2002..Lack of full response to GCV may account for cases of GvHD in patients receiving tk-transduced T lymphocytes... - Evolving concepts in the pathogenesis of hairy-cell leukaemiaEnrico Tiacci
Institute of Haematology, University of Perugia, Italy
Nat Rev Cancer 6:437-48. 2006.... - Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemiaGiovanni Roti
Laboratory of Cytogenetics and Molecular Genetics, University of Perugia, Italy
J Mol Diagn 8:254-9. 2006..Elution profiles and sequencing also identified four new variants. Our results suggest that DHPLC detects NPM1mutations as well as direct sequencing and immunohistochemistry, providing a helpful approach in the diagnosis of NPMc+ AML... - Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapyNiccolò Bolli
Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, University of Perugia, Italy
Lancet Oncol 5:64-5. 2004 - Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphomaArcangelo Liso
Institute of Hematology, University of Perugia, Policlinico, Monteluce, 06122 Perugia, Italy
Blood 108:1013-20. 2006..Our finding that NLPHL and cHL are targeted by aberrant SHM, as is DLBCL, suggests that these lymphomas may share common molecular pathogenetic events... - Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitmentMauro Di Ianni
University of Perugia, 06123 Perugia, Italy
Hum Gene Ther 16:752-64. 2005..Because of their efficient cytokine production and homing, IL-7-engineered stromal cells might be an ideal vehicle to hasten immunological reconstitution in T cell-depleted hosts... - The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissuesGabriella Sozzi
Istituto Nazionale Tumori, Milan, Italy
Haematologica 94:1307-11. 2009..These results indicate that EML4-ALK rearrangements are not specific of NSCLC and raise yet unsolved questions about their role in promoting human neoplasms... - Nucleophosmin is required for DNA integrity and p19Arf protein stabilityEmanuela Colombo
Department of Experimental Oncology, European Institute of Oncology, Milan, Italy
Mol Cell Biol 25:8874-86. 2005..Our data demonstrate that NPM regulates DNA integrity and, through Arf, inhibits cell proliferation and are consistent with a putative tumor-suppressive function of NPM... - Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysisVerena Brune
Institute for Cell Biology Tumor Research, University of Duisburg Essen Medical School, 45122 Essen, Germany
J Exp Med 205:2251-68. 2008..Thus, these findings shed new light on the nature of L&H cells, reveal several novel pathogenetic mechanisms in NLPHL, and may help in differential diagnosis and lead to novel therapeutic strategies... - Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemiaFrancesco Lo-Coco
Department of Biopathology, University Tor Vergata, Via Montpellier 1, 00161 Rome, Italy
Haematologica 93:1017-24. 2008..The aim of this study was to verify this prospectively in a large group of patients... - Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotypeSusanne Schnittger
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilian s University, Munich, Germany
Blood 106:3733-9. 2005..In conclusion, this study demonstrates that NPM1+/FLT3-LM- mutations are an independent predictor for a favorable outcome in AML with normal karyotype... - Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosminRamiro Garzon
Departments of Medicine and Molecular Virology and Human Genetics, Comprehensive Cancer Center, and College of Pharmacology, Ohio State University, Columbus, OH 43221, USA
Proc Natl Acad Sci U S A 105:3945-50. 2008..Moreover, we found that miR-155 was strongly but independently associated with FLT3-ITD mutations... - Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenanceMyriam Alcalay
IFOM IEO Campus, Via Adamello 16, 20139, Milan, Italy
Blood 106:899-902. 2005..The molecular signature of NPMc+ AML includes up-regulation of several genes putatively involved in the maintenance of a stem-cell phenotype, suggesting that NPMc+ AML may derive from a multipotent hematopoietic progenitor... - T-bet-positive and IRTA1-positive monocytoid B cells differ from marginal zone B cells and epithelial-associated B cells in their antigen profile and topographical distributionKorinna Johrens
Institute for Pathology, Charite, Campus Benjamin Franklin, Medical University Berlin, Germany
Haematologica 90:1070-7. 2005..To clarify this issue we studied the antigen profile and topographical distribution of these cell types... - Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotypeGiovanni Cazzaniga
Centro Ricerca Tettamanti, Clinica Pediatrica University of Milano Bicocca, Ospedale San Gerardo, 20052 Monza, Italy
Blood 106:1419-22. 2005.... - Pathobiology of primary mediastinal B-cell lymphomaStefano A Pileri
Institute of Haematology Seragnoli, Bologna University, Policinico S Orsola, Via Massarenti 9, 40138, Bologna, Italy
Leuk Lymphoma 44:S21-6. 2003..However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgV(H) gene crippling mutations... - Epstein-barr virus infection of monocytoid B-cell proliferates: an early feature of primary viral infection?Ioannis Anagnostopoulos
Consultation and Reference Center for Hematopathology at the Institute of Pathology, Charite, Campus Benjamin Franklin, Medical University, Berlin, Germany
Am J Surg Pathol 29:595-601. 2005.... - Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patientsPier Luigi Zinzani
Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
Haematologica 87:1258-64. 2002.... - Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphomaLluis Colomo
Department of Pathology, Hospital Clinic, Institut de Recerca Biomèdica August Pi i Sunyer, University of Barcelona, Spain
Blood 101:78-84. 2003..In conclusion, differentiation profile was associated with particular clinicopathological features but was not essential to predicting outcome in DLBCL patients... - Relevance of CD79a expression for T-cell lineage attribution in CD7+/CD3- acute lymphoblastic leukemiaErica Finolezzi
Dipartimento di Biotecnologie Cellulari ed Ematologia, Sezione di Ematologia, University La Sapienza, Rome, Italy
Haematologica 87:ELT41. 2002 - Nucleophosmin regulates the stability and transcriptional activity of p53Emanuela Colombo
European Institute of Oncology, Department of Experimental Oncology, Via Ripamonti 435, 20141 Milan, Italy
Nat Cell Biol 4:529-33. 2002..These findings indicate that NPM is a crucial regulator of p53 and suggest that alterations of the NPM function by NPM fusion proteins might lead to deregulation of p53 in tumours... - Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activityLuis Hernandez
Centro de Investigación delCáncer, Centro Superior de Investigaciones Científicas University of Salamanca, Salamanca, Spain
Am J Pathol 160:1487-94. 2002..In conclusion, these findings indicate that the TFG may use a variety of intronic breakpoints in ALK rearrangements generating fusion proteins of different molecular weights, but with similar transforming potential than NPM-ALK... - Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaPier Luigi Zinzani
Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
J Clin Oncol 22:2654-61. 2004..We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab... - Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic scorePhilip Went
, Hematology and Hematopathology Units, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
J Clin Oncol 24:2472-9. 2006..The latter represents one of the first examples of mixed score (including patient- and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials... - Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition diseasePhilip Went
Institute of Pathology, University of Basel, Switzerland
Lancet Oncol 5:381-3. 2004 - Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycinPaolo Bonvini
Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera Universita di Padova, 35128 Padua, Italy
Cancer Res 62:1559-66. 2002..Our data demonstrate that NPM-ALK cell content is determined by its interaction with Hsp90 and Hsp70, and suggest that the alteration of such associations can interfere with NPM-ALK function in ALCL cells... - Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's diseaseTeresa Marafioti
Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
Haematologica 89:957-64. 2004..In this paper, we have evaluated the usefulness of the pan-leukocyte marker LSP1 and the transcription factor PU.1 for resolving such diagnostic problems... - Lymphoplasmacytic lymphoma and marginal zone lymphoma: diagnostic challengesStefano A Pileri
Institute of Hematology and Clinical Oncology, Bologna University
Haematologica 90:148. 2005 - Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulinsStefano A Pileri
Istituto di Ematologia e Oncologia Medica, L e A Seràgnoli Unità Cliniche e di Anatomia Patologica, Universita di Bologna, Bologna, Italy
Am J Pathol 162:243-53. 2003..However, it differs from other aggressive B-cell lymphomas in that it shows defective immunoglobulin production despite the expression of OCT-2, BOB.1, and PU.1 transcription factors and the lack of IgV(H) gene crippling mutations... - Nucleophosmin and cancerSilvia Grisendi
Cancer Biology and Genetics Program, Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Nat Rev Cancer 6:493-505. 2006..The aim of this review is to analyse the role of NPM in cancer, and examine how deregulated NPM activity (either gain or loss of function) can contribute to tumorigenesis... - Diffuse large B-cell lymphoma (DLBCL), anaplastic variant. report on a problematic case primarily arising in the stomachStefano Aldo Pileri
Pathologic Anatomy, Clinical and Pathology Lymphoma Units, , Bologna University, Italy
Haematologica 87:ECR40. 2002 - Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arraysPier Luigi Zinzani
Pathologic Anatomy and Lymphoma Unit, Institute of Haematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
Haematologica 90:341-7. 2005..Patients with diffuse large B-cell lymphoma (DLBCL) could benefit from integration of well-established bioclinical prognostic factors with new tools - such as micro-arrays - exploring aberrant gene and/or protein expression... - Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomasPier Paolo Piccaluga
Molecular Pathology Laboratory, Unit of Hematopathology, Department of Hematology and Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
Haematologica 93:1033-8. 2008..Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned...